ASO Visual Abstract: Selective Lymphadenectomy for Salvage Esophagectomy in Patients with Esophageal Squamous Cell Carcinoma Shuhei MayanagiRyoma HanedaYasuhiro Tsubosa ASO Visual Abstract 05 May 2022 Pages: 4872 - 4872
Primary Tumor Resection for Stage IV Non-small-cell Lung Cancer Without Progression After First-Line Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Treatment: A Retrospective Case–Control Study Shuenn-Wen KuoPei-Hsing ChenJin-Shing Chen Thoracic Oncology 07 March 2022 Pages: 4873 - 4884
ASO Author Reflection: Primary Tumor Resection for Stage IV Lung Cancer after Epidermal Growth Factor Receptor–Tyrosine Kinase Inhibitor Pei-Hsing ChenShuenn-Wen KuoJin-Shing Chen ASO Author Reflections 21 March 2022 Pages: 4885 - 4886
ASO Visual Abstract: Primary Tumor Resection for Stage IV Non-Small-Cell Lung Cancer Without Progression After First-Line Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Treatment: A Retrospective Case-Control Study Shuenn-Wen KuoPei-Hsing ChenJin-Shing Chen ASO Visual Abstract 15 May 2022 Pages: 4887 - 4888
Prognostic Value of a Modified Albumin–Bilirubin Score Designed for Patients with Esophageal Squamous Cell Carcinoma After Radical Resection Takahiro ShinozukaMitsuro KandaYasuhiro Kodera Thoracic Oncology 05 April 2022 Pages: 4889 - 4896
ASO Author Reflections: Optimized Cutoff Value of Albumin–Bilirubin Score to Predict Prognosis of Patients with Esophageal Squamous Cell Carcinoma After Radical Resection Takahiro ShinozukaMitsuro KandaYasuhiro Kodera ASO Author Reflections 01 April 2022 Pages: 4897 - 4898
ASO Visual Abstract: Prognostic Value of a Modified Albumin–Bilirubin Grade Designed for Patients with Esophageal Squamous Cell Carcinoma after Radical Resection Takahiro ShinozukaMitsuro KandaYasuhiro Kodera ASO Visual Abstract 19 April 2022 Pages: 4899 - 4899
Prognostic Impact of Number of Organ Invasions in Patients with Surgically Resected Thymoma Soichiro FunakiNaoko OseYasushi Shintani Thoracic Oncology 09 April 2022 Pages: 4900 - 4907
ASO Visual Abstract: Prognostic Impact of the Number of Organ Invasions in Patients with Surgically Resected Thymoma Soichiro FunakiNaoko OseYasushi Shintani ASO Visual Abstract 13 April 2022 Pages: 4908 - 4908
Skeletonizing En Bloc Esophagectomy Revisited: Oncologic Outcome in Association with the Presence of Thoracic Duct Lymph Nodes Ha Eun KimYoung Ho YangDae Joon Kim Thoracic Oncology 19 April 2022 Pages: 4909 - 4917
ASO Author Reflections: The Role of Skeletonizing en bloc Esophagectomy in Esophageal Squamous Cell Carcinoma Dae Joon KimHa Eun Kim ASO Author Reflections 13 April 2022 Pages: 4918 - 4919
ASO Visual Abstract: Skeletonizing En Bloc Esophagectomy Revisited—Oncologic Outcome in Association with Presence of Thoracic Duct Lymph Nodes Ha Eun KimYoung Ho YangDae Joon Kim ASO Visual Abstract Open access 02 April 2022 Pages: 4920 - 4921
Correction to: Primary Tumor Resection for Stage IV Non-small-cell Lung Cancer Without Progression After First-Line Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Treatment: A Retrospective Case–Control Study Shuenn-Wen KuoPei-Hsing ChenJin-Shing Chen Correction 09 April 2022 Pages: 4922 - 4922
Correction to: Establishment of Minimal Clinically Important Improvement for Patient-Reported Symptoms to Define Recovery After Video-Assisted Thoracoscopic Surgery Wei XuWei DaiQiuling Shi Correction 12 April 2022 Pages: 4923 - 4923
Comprehensive Analysis of Molecular Biologic Characteristics of Pancreatic Ductal Adenocarcinoma Concomitant with Intraductal Papillary Mucinous Neoplasm Masahiro TsujimaeAtsuhiro MasudaYuzo Kodama Translational Research 23 May 2022 Pages: 4924 - 4934
ASO Visual Abstract: Comprehensive Analysis of Molecular Biological Characteristics of Pancreatic Ductal Adenocarcinoma Concomitant with Intraductal Papillary Mucinous Neoplasm Masahiro TsujimaeAtsuhiro MasudaYuzo Kodama ASO Visual Abstract 15 May 2022 Pages: 4935 - 4936
Inhibition of Clusterin Represses Proliferation by Inducing Cellular Senescence in Pancreatic Cancer Suguru MitsufujiYoshifumi IwagamiHidetoshi Eguchi Translational Research 10 April 2022 Pages: 4937 - 4946
ASO Author Reflections: A Novel Mechanism of Suppressing Proliferation After Inhibition of Clusterin in Pancreatic Cancer Suguru MitsufujiYoshifumi IwagamiHidetoshi Eguchi ASO Author Reflections 26 May 2022 Pages: 4947 - 4948
ASO Visual Abstract: Inhibition of Clusterin Represses Proliferation by Inducing Cellular Senescence in Pancreatic Cancer Suguru MitsufujiYoshifumi IwagamiHidetoshi Eguchi ASO Visual Abstract 12 May 2022 Pages: 4949 - 4950
Evaluation of HLA-E Expression Combined with Natural Killer Cell Status as a Prognostic Factor for Advanced Gastric Cancer Takeshi MorinagaMasaaki IwatsukiHideo Baba Translational Research 12 April 2022 Pages: 4951 - 4960
ASO Visual Abstract: Evaluation of HLA-E Expression Combined with Natural-Killer Cell Status as a Prognostic Factor for Advanced Gastric Cancer Takeshi MorinagaMasaaki IwatsukiHideo Baba ASO Visual Abstract 02 June 2022 Pages: 4961 - 4961
Recurrence After Resection of Pancreatic Cancer: Can Radiomics Predict Patients at Greatest Risk of Liver Metastasis? Constantinos P. ZambirinisAbhishek MidyaWilliam R. Jarnagin Pancreatic Tumors 03 April 2022 Pages: 4962 - 4974
ASO Author Reflections: Predicting Pancreatic Cancer Liver Metastasis by Integrating Primary Tumor Clinicopathologic Features and Liver Radiomics Constantinos P. ZambirinisWilliam R. Jarnagin ASO Author Reflections 05 April 2022 Pages: 4975 - 4976
ASO Visual Abstract: Recurrence After Resection of Pancreatic Cancer – Can Radiomics Predict Patients at Greatest Risk of Liver Metastasis? Constantinos P. ZambirinisAbhishek MidyaWilliam R. Jarnagin ASO Visual Abstract 07 April 2022 Pages: 4977 - 4978
Resectability Status of Pancreatic Cancer Having Tumor Contact with an Aberrant Right Hepatic Artery: Is Upfront Surgery Justified? Yuya MiuraKatsuhisa OhgiKatsuhiko Uesaka Pancreatic Tumors 01 April 2022 Pages: 4979 - 4988
ASO Author Reflections: Pancreatic Cancer Having Tumor Contact with an Aberrant Right Hepatic Artery Should be Regarded as Technically Resectable but Oncologically Borderline-Resectable Yuya MiuraKatsuhisa OhgiKatsuhiko Uesaka ASO Author Reflections 21 April 2022 Pages: 4989 - 4990
ASO Visual Abstract: Resectability Status of Pancreatic Cancer Having Tumor Contact with an Aberrant Right Hepatic Artery: Is Upfront Surgery Justified? Yuya MiuraKatsuhisa OhgiKatsuhiko Uesaka ASO Visual Abstract 22 April 2022 Pages: 4991 - 4991
The Association Between Neoadjuvant Therapy and Pathological Outcomes in Pancreatic Cancer Patients After Resection: Prognostic Significance of Microscopic Venous Invasion Hidemasa KuboKatsuhisa OhgiKatsuhiko Uesaka Pancreatic Tumors 03 April 2022 Pages: 4992 - 5002
ASO Author Reflections: Neoadjuvant Therapy for Pancreatic Cancer may Reduce Microscopic Venous Invasion, Which is an Independent Prognostic Factor Associated with Liver Recurrence Hidemasa KuboKatsuhisa OhgiKatsuhiko Uesaka ASO Author Reflections 05 April 2022 Pages: 5003 - 5004
ASO Visual Abstract: The Association Between Neoadjuvant Therapy and Pathological Outcomes in Pancreatic Cancer Patients After Resection: Prognostic Significance of Microscopic Venous Invasion Hidemasa KuboKatsuhisa OhgiKatsuhiko Uesaka ASO Visual Abstract 08 April 2022 Pages: 5005 - 5006
Predictors of Long-Term Survival in Pancreatic Ductal Adenocarcinoma after Pancreatectomy: TP53 and SMAD4 Mutation Scoring in Combination with CA19-9 Masato OnoYusuke OnoSatoshi Hirano Pancreatic Tumors 10 April 2022 Pages: 5007 - 5019
ASO Author Reflections: Constructed Scoring System Using TP53 and SMAD4 Mutations Combined with Carbohydrate Antigen 19-9 in Pancreatic Ductal Adenocarcinoma Masato OnoToru NakamuraSatoshi Hirano ASO Author Reflections 09 May 2022 Pages: 5020 - 5021
Radiographical Evaluation of Tumor Immunosuppressive Microenvironment and Treatment Outcomes in Gastric Cancer: A Retrospective, Multicohort Study Jian-Xian LinJun-Peng LinChang-Ming Huang Pancreatic Tumors 16 March 2022 Pages: 5022 - 5033
ASO Author Reflections: Radiomic Immunosuppressive Scoring System for Predicting Prognosis and Chemotherapy Benefit in Gastric Cancer Jun-Peng LinJian-Xian LinChang-Ming Huang ASO Author Reflections 11 May 2022 Pages: 5034 - 5035
ASO Visual Abstract: Radiographical Evaluation of Tumor Immunosuppressive Microenvironment and Treatment Outcomes in Gastric Cancer: A Retrospective, Multicohort Study Jian-Xian LinJun-Peng LinChang-Ming Huang ASO Visual Abstract 09 May 2022 Pages: 5036 - 5037
Optimizing Indications for Conversion Surgery Based on Analysis of 454 Consecutive Japanese Cases with Unresectable Pancreatic Cancer Who Received Modified FOLFIRINOX or Gemcitabine Plus Nab-paclitaxel: A Single-Center Retrospective Study Yuta UshidaYosuke InoueYu Takahashi Pancreatic Tumors 16 March 2022 Pages: 5038 - 5050
ASO Author Reflections: What are the Indications for Conversion Surgery for Initially Unresectable Pancreatic Cancer Who Received Modified FOLFIRINOX or Gemcitabine Plus Nab-paclitaxel? Is Surgery Really Worthwhile after Sufficient Chemotherapy? Yuta UshidaYosuke InoueYu Takahashi ASO Author Reflections 03 April 2022 Pages: 5051 - 5052
ASO Visual Abstract: Optimizing the Indications for Conversion Surgery Based on an Analysis of 454 Consecutive Japanese Cases with Unresectable Pancreatic Cancer Who Received Modified FOLFIRINOX or Gemcitabine Plus Nab-paclitaxel: A Single-Center Retrospective Study Yuta UshidaYosuke InoueYu Takahashi ASO Visual Abstract 11 April 2022 Pages: 5053 - 5054
Correction to: More is More? Total Pancreatectomy for Periampullary Cancer as an Alternative in Patients with High-Risk Pancreatic Anastomosis: A Propensity Score-Matched Analysis Anna BurelliGiampaolo PerriGiovanni Marchegiani Correction 06 April 2022 Pages: 5055 - 5055
It’s Not About the Money: Continued Treatment and Survival Outcome Disparities in Minority Rectal Cancer Patients After Controlling for Socioeconomic Factors Bianca AibuedefeKendall S. HamiltonJuan L. Poggio Colorectal Cancer 30 March 2022 Pages: 5056 - 5062
ASO Author Reflections: Inequities in Rectal Cancer Treatment and Survival Kendall S. HamiltonBianca AibuedefeJuan Lucas Poggio ASO Author Reflections 21 March 2022 Pages: 5063 - 5064
ASO Visual Abstract: It’s Not About the Money: Continued Treatment and Survival Outcome Disparities in Minority Rectal Cancer Patients After Controlling for Socioeconomic Factors Kendall S. HamiltonBianca AibuedefeJuan Lucas Poggio ASO Visual Abstract 21 April 2022 Pages: 5065 - 5065
Laparoscopic Complete Mesocolic Excision with Central Vascular Ligation (CME + CVL) for Right-Sided Colon Cancer: A New “Superior Mesenteric Artery First” Approach Wenjun LuoZhaolun CaiBo Zhang Colorectal Cancer 19 April 2022 Pages: 5066 - 5073
ASO Author Reflections: A New “Superior Mesenteric Artery-First” Approach for Complete Mesocolic Excision with Central Vascular Ligation in Laparoscopic Right Hemicolectomy Wenjun LuoTingting LuYanling Xiao ASO Author Reflections 26 April 2022 Pages: 5074 - 5075
Comparison of Standard D2 and Limited Lymph Node Dissection in Elderly Patients with Advanced Gastric Cancer Chang Seok KoJin Ho JheongChung Sik Gong Gastrointestinal Oncology 22 March 2022 Pages: 5076 - 5082
ASO Visual Abstract: Comparison of Standard D2 and Limited Lymph Node Dissection in Elderly Patients with Advanced Gastric Cancer Chang Seok KoJin Ho JheongChung Sik Gong ASO Visual Abstract 09 March 2022 Pages: 5083 - 5083
Safety and Efficacy of Intraperitoneal Paclitaxel Plus Intravenous Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX) for Gastric Cancer with Peritoneal Metastasis So Hyun KangSa-Hong MinHyung-Ho Kim Gastrointestinal Oncology 23 March 2022 Pages: 5084 - 5091
ASO Visual Abstract: Safety and Efficacy of Intraperitoneal Paclitaxel Plus Intravenous Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX) for Gastric Cancer with Peritoneal Metastasis So Hyun KangSa-Hong MinHyung-Ho Kim ASO Visual Abstract 20 April 2022 Pages: 5092 - 5093
A National Assessment of T2 Staging for Intrahepatic Cholangiocarcinoma and the Poor Prognosis Associated with Multifocality Kevin M. TurnerAaron M. DelmanGregory C. Wilson Gastrointestinal Oncology 20 April 2022 Pages: 5094 - 5102
ASO Author Reflections: Disparate Outcomes in Stage II Intrahepatic Cholangiocarcinoma: A Case for Upstaging Multifocal Tumors Kevin M. TurnerGregory C. Wilson ASO Author Reflections 28 April 2022 Pages: 5103 - 5104